{"id":527356,"date":"2021-01-22T18:32:01","date_gmt":"2021-01-22T18:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=527356"},"modified":"2021-01-22T18:32:01","modified_gmt":"2021-01-22T18:32:01","slug":"human-microbiome-market-worth-1731-million-by-2027-key-players-are-enterome-bioscience-france-seres-therapeutics-us-and-4d-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/human-microbiome-market-worth-1731-million-by-2027-key-players-are-enterome-bioscience-france-seres-therapeutics-us-and-4d-pharma_527356.html","title":{"rendered":"Human Microbiome Market Worth $1,731 Million by 2027 | Key Players are Enterome Bioscience (France), Seres Therapeutics (US), and 4D Pharma"},"content":{"rendered":"
\"Human<\/a><\/p>\n
\n
The major companies in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US), and 4D Pharma (UK).<\/div>\n<\/div>\n<\/div>\n
Human Microbiome Market Size Estimation and Analysis of Wide Range of Growth Opportunities for Industry Players.<\/div>\n

According to the new market research report “<\/strong>Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic\/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) – Global Forecast to 2027″<\/strong>, published by MarketsandMarkets™, the Human Microbiome Market is expected to grow from USD 942 million<\/span> in 2024 to USD 1,731 million<\/span> by 2027, at a CAGR of 22.5 % during the forecast period.<\/p>\n

Download PDF Brochure:
<\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=37621904<\/a><\/p>\n

Microbiomes are responsible for a wide variety of metabolic and developmental processes—from food digestion to vitamin synthesis and even brain function. They also play a major role in human conditions, such as obesity and inflammatory bowel disease. <\/p>\n

The probiotics segment to account for the largest share of the global Human Microbiome Market in 2022<\/p>\n

<\/strong>Based on product, the Human Microbiome Market is segmented into probiotics, prebiotics, foods, medical foods, diagnostic tests, and drugs. The probiotics segment is expected to account for the largest share of the Human Microbiome Market in 2022. The increasing awareness of probiotics for the prevention and treatment of various lifestyle & chronic diseases and health benefits of probiotics over conventional medicines, such as antibiotics are some of the major factors driving the growth of this segment.<\/p>\n

Browse in-depth TOC on<\/em> “<\/strong>Human Microbiome Market<\/a><\/strong>“<\/p>\n

<\/strong>82 – Tables
<\/strong>22 – Figures   
<\/strong>128 – Pages<\/p>\n

<\/strong>The therapeutics segment to account for the largest share of the market in 2022<\/p>\n

<\/strong>Based on application, the Human Microbiome Market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2022. This is due to the need for the development of reliable, precise, and quicker treatment of chronic lifestyle diseases and various other disorders.<\/p>\n

The infectious diseases segment to account for the largest share of the market in 2022<\/p>\n

<\/strong>Based on disease, the Human Microbiome Market is segmented into five categories—infectious diseases, endocrine & metabolic disorders, inflammatory diseases, cancer, and other diseases. The infectious disease segment is expected to dominate the market in 2022. This is due to the increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting microbiome modulators for infectious diseases.<\/p>\n

Request Sample Pages:
https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=37621904<\/a> <\/p>\n

<\/strong>Europe<\/span> to account for the largest share of the Human Microbiome Market in 2022<\/p>\n

<\/strong>On the basis of region, the global Human Microbiome Market is segmented into four major geographies— North America<\/span>, Europe<\/span>, the Asia Pacific<\/span>, and the Rest of the World (RoW). Europe<\/span> is expected to account for the largest share of the global Human Microbiome Market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.<\/p>\n

The major players in the Human Microbiome Market include Enterome Bioscience (France<\/span>), 4D Pharma (UK), and Seres Therapeutics (US).<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/human-microbiome-market-37621904.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

The major companies in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US), and 4D Pharma (UK). Human Microbiome Market Size Estimation and Analysis of Wide Range of Growth Opportunities for Industry Players. According to the new market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-527356","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/527356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=527356"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/527356\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=527356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=527356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=527356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}